Nicotinamide adenine dinucleotide (NAD+) inzvimbo inonyanya kutsvagurudzwa nevesainzi vari munyika nekunze kwenyika. Masayendisiti mazhinji anotenda kuti huwandu hweNAD+ hwakabatana zvakanyanya nezvirwere zvisingaperi zvine chekuita nekukwegura, zvakaita sekenza, kufuta, BP uye chirwere cheshuga.
Keratinocyte carcinoma (KC) ndiyo bundu rinonyanya kuipa muvanhu vane ganda jena, kusanganisira basal cell carcinoma (BCC) uye squamous cell carcinoma (cSCC). Munguva pfupi yapfuura, masayendisiti ekuAmerica akaburitsa nyaya yekukurukura muJ DRUGS DERMATOL pamusoro pekuwedzera NAD precursors NMN neNR kuderedza njodzi yekenza yekeratinocyte.
Munyori anofunga kuti nicotinamide (NAM), senzira yekutanga NAD+, yakaratidzwa naChoy B nevamwe masayendisiti kuderedza kuwanda kwekenza yekeratinocyte. Zvisinei, nicotinamide mononucleotide (NMN) uye nicotinamide nucleoside (NR), izvo zvinotungamirawo kugadzirwa kweNAD+, zvinogona kuva chimwe chezvinowedzera kushanda zvakanaka kuderedza kuwanda kwekenza yekeratinocyte.
Kupiwa kweNMN neNR nemuromo kunogona kuwedzera huwandu hweNAD+ zvinobudirira
Muna 2018, Sinclair DA nevamwe masayendisiti vakaratidza kuti zvichienzaniswa neNAM, kutora NMN neNR nemuromo kurapa vanhu nemakonzo kwakawedzera huwandu hweNAD+ muropa nechiropa, zvichiteerana. Nekuda kweizvozvo, NMN neNR zvakagadzira NAD+ zvinobudirira.
NMN neNR zvakachengeteka uye zviri nani kutsungirira
Mishonga yeNMN neNR yakashandiswa zvakanyanya muvanhu nemhuka, uye hapana chepfu kana migumisiro yakakomba yakataurwa kusvika pari zvino. Chidzidzo chekiriniki chakaitwa muvakadzi makumi maviri nevashanu vasati vasvika panguva yekuenda kumwedzi vane chirwere cheshuga vakatora mushonga weNMN nemuromo pachiyero che250 mg/zuva, uye vakaona kuti NMN yakawedzera kunzwa kwe insulin yemhasuru pasina kukonzera chero zviitiko zvakaipa. Chidzidzo chechipiri chekiriniki chakatarisana nemhedzisiro yeNMN supplementation pakugona kwevanomhanya kurovedza muviri. Vanhu makumi matatu nevatanhatu vakatora 300 mg/zuva (n=12), 600 mg/zuva (n=12) kana 1200 mg/zuva (n=12) NMN, uye hapana migumisiro yakaipa kana zviitiko zvakaipa zvakataurwa. Kunyangwe US Food and Drug Administration (FDA) isati yabvumidza zvinhu zviviri izvi zvekuwedzera zvekudya, mishonga yeNMN neNR inogona kutengwa zviri nyore online, uye vatengi vazhinji vakatanga kuitora, nematanho ari pakati pe500mg kusvika 1000mg/zuva. Hapana zviitiko zvakaipa zvakawanikwa.
Kana tichienzanisa neNAM, mushonga weNMN neNR unogona kuwedzera huwandu hweNAD+ zvinobudirira uye kuva nekuchengetedzeka kuri nani uye kushivirira, inova nzira yekurapa inogona kushandiswa nevanorapa ganda kuderedza njodzi yekenza yekeratinocyte. Zvisinei, ichiri kuda ruzivo rwakawanda rwekutsvagisa kwekiriniki kuti ione kuti inoshanda sei mukurapa kwekiriniki.
Mareferensi:
[1]. Kahn B, Borrelli M, Libby T. Ongororo yeNhoroondo yeNicotinamide Adenine Dinucleotide (NAD)+ Intermediates Nicotinamide Riboside neNicotinamide Mononucleotide yeKeratinocyte Carcinoma Risk Reduction. J Drugs Dermatol. 2022 Gumiguru 1;21(10):1129-1132. doi: 10.36849/JDD.6870. PMID: 36219044.
Nguva yekutumira: Gumiguru-25-2022